|
1
|
Siegel RL, Fedewa SA, Miller KD,
Goding-Sauer A, Pinheiro PS, Martinez-Tyson D and Jemal A: Cancer
statistics for hispanics/latinos 2015. CA Cancer J Clin.
65:457–480. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Culp MB, Soerjomataram I, Efstathiou JA,
Bray F and Jemal A: Recent global patterns in prostate cancer
incidence and mortality rates. Eur Urol. 77:38–52. 2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Egan A, Dong Y, Zhang H, Qi Y, Balk SP and
Sartor O: Castration-resistant prostate cancer: Adaptive responses
in the androgen axis. Cancer Treat Rev. 40:426–433. 2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kaboré FA, Zango B, Kambou T, Ouédraogo
AS, Bambara A, Yaméogo C, Kirakoya B and Lompo O: Prostate cancer
disease characteristics at the time of diagnosis and initial
treatment offered in a tertiary hospital at ouagadougou (Burkina
Faso). Open J Urol. 4:7–12. 2014.
|
|
5
|
Sakar Y, Duca FA, Langelier B, Devime F,
Blottiere H, Delorme C, Renault P and Covasa M: Impact of high-fat
feeding on basic helix-loop-helix transcription factors controlling
enteroendocrine cell differentiation. Int J Obes (Lond). 38:1482.
2014.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Mermod N, Williams TJ and Tjian R:
Enhancer binding factors AP-4 and AP-1 act in concert to activate
SV40 late transcription in vitro. Nature. 332:557–561.
1988.PubMed/NCBI View
Article : Google Scholar
|
|
7
|
Lee SU, Song HO, Lee W, Singaravelu G, Yu
JR and Park WY: Identification and characterization of a putative
basic helix-loop-helix (bHLH) transcription factor interacting with
calcineurin in C elegans. Mol Cells. 28:455–461. 2009.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Atchley WR and Fitch WM: A natural
classification of the basic helix-loop-helix class of transcription
factors. Proc Natl Acad Sci USA. 94:5172–5176. 1997.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Wei J, Yang P, Zhang T, Chen Z, Chen W,
Wanglin L, He F, Wei F, Huang D, Zhong J, et al: Overexpression of
transcription factor activating enhancer binding protein 4 (TFAP4)
predicts poor prognosis for colorectal cancer patients. Exp Ther
Med. 14:3057–3061. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Xinghua L, Bo Z, Yan G, Lei W, Changyao W,
Qi L, Lin Y, Kaixiong T, Guobin W and Jianying C: The
overexpression of AP-4 as a prognostic indicator for gastric
carcinoma. Med Oncol. 29:871–877. 2012.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Gong H, Han S, Yao H, Zhao H and Wang Y:
AP-4 predicts poor prognosis in non-small cell lung cancer. Mol Med
Rep. 10:336–340. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Song J, Xie C, Jiang L, Wu G, Zhu J, Zhang
S, Tang M, Song L and Li J: Transcription factor AP-4 promotes
tumorigenic capability and activates the Wnt/β-catenin pathway in
hepatocellular carcinoma. Theranostics. 8:3571–3583.
2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Jaeckel S, Kaller M, Jackstadt R, Götz U,
Müller S, Boos S, Horst D, Jung P and Hermeking H: Ap4 is rate
limiting for intestinal tumor formation by controlling the
homeostasis of intestinal stem cells. Nat Commun.
9(3573)2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Wu H, Liu X, Gong P, Song W, Zhou M, Li Y,
Zhao Z and Fan H: Elevated TFAP4 regulates lncRNA TRERNA1 to
promote cell migration and invasion in gastric cancer. Oncol Rep.
40:923–931. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Huang T, Chen QF, Chang BY, Shen LJ, Li W,
Wu PH and Fan WJ: TFAP4 promotes hepatocellular carcinoma invasion
and metastasis via activating the PI3K/AKT signaling pathway. Dis
Markers. 2019(7129214)2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Chen C, Cai Q, He W, Lam TB, Lin J, Zhao
Y, Chen X, Gu P, Huang H, Xue M, et al: AP4 modulated by the
PI3K/AKT pathway promotes prostate cancer proliferation and
metastasis of prostate cancer via upregulating L-plastin. Cell
Death Dis. 8(e3060)2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Krebs M, Solimando AG, Kalogirou C,
Marquardt A, Frank T, Sokolakis I, Hatzichristodoulou G, Kneitz S,
Bargou R, Kübler H, et al: miR-221-3p regulates VEGFR2 expression
in high-risk prostate cancer and represents an escape mechanism
from sunitinib in vitro. J Clin Mad. 9(670)2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Mahn R, Heukamp LC, Rogenhofer S, Van
Ruecker A, Müller SC and Ellinger JR: Circulating microRNAs (miRNA)
in serum of patients with prostate cancer. Urology.
77:1265.e1269–1265.e1216. 2011.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Xue C, Yu DM, Gherardi S, Koach J, Milazzo
G, Gamble L, Liu B, Russell A, Liu T, Cheung TB, et al: Abstract
2450: MYCN and TFAP4 promote neuroblastoma malignancy by
cooperating in the regulation a subset of target genes involved in
cancer cell growth and metastasis. Cancer Res. 76 (Suppl
14)(S2450)2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Wu M, Wang J, Tang W, Zhan X, Li Y, Peng
Y, Huang X, Bai Y, Zhao J, Li A, et al: FOXK1 interaction with FHL2
promotes proliferation, invasion and metastasis in colorectal
cancer. Oncogenesis. 5(e271)2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Li P, Yu Z, He L, Zhou D, Xie S, Hou H and
Geng X: Knockdown of FOXK1 inhibited the proliferation, migration
and invasion in hepatocellular carcinoma cells. Biomed
Pharmacother. 92:270–276. 2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Chen D, Wang K, Li X, Jiang M, Ni L, Xu B,
Chu Y, Wang W, Wang H, Kang H, et al: FOXK1 plays an oncogenic role
in the development of esophageal cancer. Biochem Biophys Res
Commun. 494:88–94. 2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Ji ZG, Jiang HT and Zhang PS: FOXK1
promotes cell growth through activating wnt/β-catenin pathway and
emerges as a novel target of miR-137 in glioma. Am J Transl Res.
10:1784–1792. 2018.PubMed/NCBI
|
|
25
|
Chen F, Xiong W, Dou K and Ran Q:
Knockdown of FOXK1 suppresses proliferation, migration, and
invasion in prostate cancer cells. Oncol Res. 25:1261–1267.
2017.PubMed/NCBI View Article : Google Scholar
|
